New Cholesterol-Lowering Drugs Shows Exciting Promise

Taking a different path, PCSK9 inhibitors reduce LDL levels in statin-intolerant patients.

For patients who are unable to reap cholesterol-lowering benefits from the drugs known as statins due to intolerable side effects, technology may soon offer an alternative and effective treatment.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access